CapForce, Inc. (CFOR)
6.02
-0.88
(-12.75%)
USD |
OTCM |
Nov 05, 16:00
CapForce Enterprise Value : 76.45M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 76.45M |
| November 04, 2026 | 87.36M |
| November 03, 2026 | 122.70M |
| November 02, 2026 | 122.70M |
| October 30, 2026 | 122.70M |
| October 29, 2026 | 113.40M |
| October 28, 2026 | 107.20M |
| October 27, 2026 | 113.40M |
| October 26, 2026 | 51.90M |
| October 23, 2026 | 51.90M |
| October 22, 2026 | 50.91M |
| October 21, 2026 | 51.78M |
| October 20, 2026 | 51.78M |
| October 19, 2026 | 51.78M |
| October 16, 2026 | 45.21M |
| October 15, 2026 | 51.90M |
| October 14, 2026 | 51.90M |
| October 13, 2026 | 50.95M |
| October 12, 2026 | 51.33M |
| October 09, 2026 | 51.33M |
| October 08, 2026 | 50.99M |
| October 07, 2026 | 52.03M |
| October 06, 2026 | 51.90M |
| October 05, 2026 | 52.03M |
| October 02, 2026 | 52.03M |
| Date | Value |
|---|---|
| October 01, 2026 | 51.90M |
| September 30, 2026 | 51.90M |
| September 29, 2026 | 51.90M |
| September 28, 2026 | 50.17M |
| September 25, 2026 | 51.90M |
| September 24, 2026 | 51.90M |
| September 23, 2026 | 51.90M |
| September 22, 2026 | 43.07M |
| September 21, 2026 | 41.49M |
| September 18, 2026 | 44.96M |
| September 17, 2026 | 44.96M |
| September 16, 2026 | 44.96M |
| September 15, 2026 | 39.63M |
| September 14, 2026 | 48.93M |
| September 11, 2026 | 54.51M |
| September 10, 2026 | 58.86M |
| September 09, 2026 | 58.86M |
| September 08, 2026 | 65.67M |
| September 04, 2026 | 65.67M |
| September 03, 2026 | 65.67M |
| September 02, 2026 | 65.67M |
| September 01, 2026 | 65.67M |
| August 31, 2026 | 65.67M |
| August 28, 2026 | 65.68M |
| August 27, 2026 | 65.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Phio Pharmaceuticals Corp. | -3.702M |
| Agenus, Inc. | 539.10M |
| Amgen, Inc. | 289.78B |
| Anika Therapeutics, Inc. | 245.53M |
| BioCryst Pharmaceuticals, Inc. | 2.407B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 42.47M |
| Revenue (Quarterly) | 50.00M |
| Total Expenses (Quarterly) | 7.529M |
| EPS Diluted (Quarterly) | 3.384 |
| Gross Profit Margin (Quarterly) | 89.90% |
| Profit Margin (Quarterly) | 84.94% |
| Earnings Yield | 88.56% |
| Operating Earnings Yield | 96.42% |
| Normalized Earnings Yield | 88.56 |